Sol-Gel's rosacea drug clears late-stage hurdle; uniQure's hemophilia gene therapy impresses with PhII data
→ Israel’s Sol-Gel Technologies‘ microencapsulation platform — designed to entrap active ingredients in porous silica microcapsules to address the limitations of topical drug delivery by stabilizing the ingredients, extending drug delivery time and reducing potential irritation — was validated when its papulopustular rosacea product made of microencapsulated benzoyl peroxide, Epsolay, cleared twin late-stage studies. “While we expected to see strong efficacy and tolerability with Epsolay, the rapid efficacy was a standout in our Phase 3 studies,” said Alon Seri-Levy, Sol-Gel’s chief, in a statement.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.